Scientists at Institut Pasteur in France have repurposed DPP4 inhibitors, used to treat type 2 diabetes mellitus, to boost the body's immune response to tumors.
While immuno-oncology agents like the PD-1 and PD-L1 inhibitors have revolutionized cancer care by preventing checkpoint blockade, scientists at the Institut Pasteur have discovered another way to manipulate the body's immune response to a tumor—increased infiltration of T-cells to the tumor site.
In their article published in Nature Immunology, the authors show that inhibition of the enzyme dipeptidylpeptidase 4 (DPP4), also a target in diabetes, helps boosts the body's immune response to a tumor by maintaining the activity of CXCL10 and CXCR3 receptors. Preserving the activity of these receptors helps the influx of immune cells at the tumor site, which can help reject tumor growth.
Read more on ScienceDaily: http://bit.ly/1L2zU7v
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More